These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 27260215)

  • 1. Advanced assessment of the physicochemical characteristics of Remicade® and Inflectra® by sensitive LC/MS techniques.
    Fang J; Doneanu C; Alley WR; Yu YQ; Beck A; Chen W
    MAbs; 2016; 8(6):1021-34. PubMed ID: 27260215
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hydrophilic Interaction Chromatography Hyphenated with Mass Spectrometry: A Powerful Analytical Tool for the Comparison of Originator and Biosimilar Therapeutic Monoclonal Antibodies at the Middle-up Level of Analysis.
    D'Atri V; Fekete S; Beck A; Lauber M; Guillarme D
    Anal Chem; 2017 Feb; 89(3):2086-2092. PubMed ID: 28208257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of middle- and bottom-up mass spectrometry in forced degradation studies of bevacizumab and infliximab.
    Dyck YFK; Rehm D; Winkler K; Sandig V; Jabs W; Parr MK
    J Pharm Biomed Anal; 2023 Oct; 235():115596. PubMed ID: 37540995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Stability Studies of Different Infliximab and Biosimilar CT-P13 Clinical Solutions by Combined Use of Physicochemical Analytical Techniques and Enzyme-Linked Immunosorbent Assay (ELISA).
    Hermosilla J; Sánchez-Martín R; Pérez-Robles R; Salmerón-García A; Casares S; Cabeza J; Cuadros-Rodríguez L; Navas N
    BioDrugs; 2019 Apr; 33(2):193-205. PubMed ID: 30875076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Multidimensional Analytical Comparison of Remicade and the Biosimilar Remsima.
    Pisupati K; Tian Y; Okbazghi S; Benet A; Ackermann R; Ford M; Saveliev S; Hosfield CM; Urh M; Carlson E; Becker C; Tolbert TJ; Schwendeman SP; Ruotolo BT; Schwendeman A
    Anal Chem; 2017 May; 89(9):4838-4846. PubMed ID: 28365979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rapid comparison of a candidate biosimilar to an innovator monoclonal antibody with advanced liquid chromatography and mass spectrometry technologies.
    Xie H; Chakraborty A; Ahn J; Yu YQ; Dakshinamoorthy DP; Gilar M; Chen W; Skilton SJ; Mazzeo JR
    MAbs; 2010; 2(4):379-94. PubMed ID: 20458189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of originator and biosimilar therapeutic monoclonal antibodies using comprehensive two-dimensional liquid chromatography coupled with time-of-flight mass spectrometry.
    Sorensen M; Harmes DC; Stoll DR; Staples GO; Fekete S; Guillarme D; Beck A
    MAbs; 2016 Oct; 8(7):1224-1234. PubMed ID: 27362833
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile characterization of glycosylation modification in CTLA4-Ig fusion proteins by liquid chromatography-mass spectrometry.
    Zhu L; Guo Q; Guo H; Liu T; Zheng Y; Gu P; Chen X; Wang H; Hou S; Guo Y
    MAbs; 2014; 6(6):1474-85. PubMed ID: 25484062
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biosimilarity under stress: A forced degradation study of Remicade® and Remsima™.
    Pisupati K; Benet A; Tian Y; Okbazghi S; Kang J; Ford M; Saveliev S; Sen KI; Carlson E; Tolbert TJ; Ruotolo BT; Schwendeman SP; Schwendeman A
    MAbs; 2017 Oct; 9(7):1197-1209. PubMed ID: 28787231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Physicochemical and functional comparability between the proposed biosimilar rituximab GP2013 and originator rituximab.
    Visser J; Feuerstein I; Stangler T; Schmiederer T; Fritsch C; Schiestl M
    BioDrugs; 2013 Oct; 27(5):495-507. PubMed ID: 23649935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The criticality of high-resolution N-linked carbohydrate assays and detailed characterization of antibody effector function in the context of biosimilar development.
    Brady LJ; Velayudhan J; Visone DB; Daugherty KC; Bartron JL; Coon M; Cornwall C; Hinckley PJ; Connell-Crowley L
    MAbs; 2015; 7(3):562-70. PubMed ID: 25898160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical characterization of Remsima.
    Jung SK; Lee KH; Jeon JW; Lee JW; Kwon BO; Kim YJ; Bae JS; Kim DI; Lee SY; Chang SJ
    MAbs; 2014; 6(5):1163-77. PubMed ID: 25517302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar.
    Lerch TF; Sharpe P; Mayclin SJ; Edwards TE; Polleck S; Rouse JC; Zou Q; Conlon HD
    BioDrugs; 2020 Feb; 34(1):77-87. PubMed ID: 31650490
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies biosimilarity assessment using transient isotachophoresis capillary zone electrophoresis-tandem mass spectrometry.
    Gahoual R; Biacchi M; Chicher J; Kuhn L; Hammann P; Beck A; Leize-Wagner E; François YN
    MAbs; 2014; 6(6):1464-73. PubMed ID: 25484058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of Glycoforms and Amino Acids in Infliximab and a Biosimilar Product Using New Method with LC/TOF-MS.
    Tsuda M; Otani Y; Yonezawa A; Masui S; Ikemi Y; Denda M; Sato Y; Nakagawa S; Omura T; Imai S; Nakagawa T; Hayakari M; Matsubara K
    Biol Pharm Bull; 2018 Nov; 41(11):1716-1721. PubMed ID: 30158337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab).
    Hong J; Lee Y; Lee C; Eo S; Kim S; Lee N; Park J; Park S; Seo D; Jeong M; Lee Y; Yeon S; Bou-Assaf G; Sosic Z; Zhang W; Jaquez O
    MAbs; 2017; 9(2):364-382. PubMed ID: 28005456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in structural mass spectrometry methods in the context of biosimilarity assessment: from sequence heterogeneities to higher order structures.
    Castel J; Delaux S; Hernandez-Alba O; Cianférani S
    J Pharm Biomed Anal; 2023 Nov; 236():115696. PubMed ID: 37713983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product.
    Saleem R; Cantin G; Wikström M; Bolton G; Kuhns S; McBride HJ; Liu J
    Pharm Res; 2020 May; 37(6):114. PubMed ID: 32476063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A rapid method for relative quantification of
    Segu Z; Stone T; Berdugo C; Roberts A; Doud E; Li Y
    MAbs; 2020; 12(1):1750794. PubMed ID: 32249667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physicochemical Characterization, Glycosylation Pattern and Biosimilarity Assessment of the Fusion Protein Etanercept.
    Montacir O; Montacir H; Springer A; Hinderlich S; Mahboudi F; Saadati A; Parr MK
    Protein J; 2018 Apr; 37(2):164-179. PubMed ID: 29411222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.